Newron Pharmaceuticals S.p.A.
Stock Forecast, Prediction & Price Target
Newron Pharmaceuticals S.p.A. Financial Estimates
Newron Pharmaceuticals S.p.A. Revenue Estimates
Newron Pharmaceuticals S.p.A. EBITDA Estimates
Newron Pharmaceuticals S.p.A. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| CHF5.76M N/A | CHF6.09M 5.76% | CHF9.05M 48.62% | Avg: CHF25.74M Low: CHF25.74M High: CHF25.74M avg. 184.29% | Avg: CHF40.64M Low: CHF40.64M High: CHF40.64M avg. 57.84% | Avg: CHF116.25M Low: CHF116.25M High: CHF116.25M avg. 186.04% | Avg: CHF182.01M Low: CHF182.01M High: CHF182.01M avg. 56.55% |
Net Income
% change YoY
| CHF-14.90M N/A | CHF-17.49M -17.39% | CHF-16.22M 7.25% | Avg: CHF5.36M Low: CHF5.36M High: CHF5.36M avg. 133.06% | Avg: CHF23.31M Low: CHF23.31M High: CHF23.31M avg. 334.66% | Avg: CHF61.43M Low: CHF61.43M High: CHF61.43M avg. 163.52% | Avg: CHF108.25M Low: CHF108.25M High: CHF108.25M avg. 76.19% |
EBITDA
% change YoY
| CHF-12.31M N/A | CHF-13.26M -7.75% | CHF-11.83M 10.81% | Avg: CHF-25.74M Low: CHF-25.74M High: CHF-25.74M avg. -117.63% | Avg: CHF-40.64M Low: CHF-40.64M High: CHF-40.64M avg. -57.84% | Avg: CHF-116.25M Low: CHF-116.25M High: CHF-116.25M avg. -186.04% | Avg: CHF-182.01M Low: CHF-182.01M High: CHF-182.01M avg. -56.55% |
EPS
% change YoY
| -$0.84 N/A | -$0.98 -16.66% | -$0.91 7.14% | Avg: $0.3 Low: $0.3 High: $0.3 avg. 133.02% | Avg: $1.31 Low: $1.31 High: $1.31 avg. 334.66% | Avg: $3.44 Low: $3.44 High: $3.44 avg. 163.52% | Avg: $6.07 Low: $6.07 High: $6.07 avg. 76.19% |
Operating Expenses
% change YoY
| CHF17.78M N/A | CHF19.67M 10.64% | CHF20.68M 5.13% | Avg: CHF33.11M Low: CHF33.11M High: CHF33.11M avg. 60.08% | Avg: CHF52.27M Low: CHF52.27M High: CHF52.27M avg. 57.84% | Avg: CHF149.51M Low: CHF149.51M High: CHF149.51M avg. 186.04% | Avg: CHF234.08M Low: CHF234.08M High: CHF234.08M avg. 56.55% |
FAQ
What is Newron Pharmaceuticals S.p.A. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 176.86% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is 5.36M, average is 5.36M and high is 5.36M.
What is Newron Pharmaceuticals S.p.A. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 121.18% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is CHF25.74M, average is CHF25.74M and high is CHF25.74M.
What is Newron Pharmaceuticals S.p.A. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 176.85% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is $0.3, average is $0.3 and high is CHF0.30.